Comparison of colistin / rifampin combination with colistin / meropenem combination in the treatment of ventilator-dependent upper respiratory tract (VAP) induced by Acinetobacter: a randomized controlled clinical trial

Phase 2

Recruiting

• Conditions: Ventilator-induced pneumonia.; Ventilator associated pneumonia; J95.851

• Registration Number: IRCT20150721023282N22
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Age over 18 years
Under mechanical ventilation (intubation) for more than 48 hours
VAP diagnosis
Growth of carbapenem (meropenem)-resistant Acinetobacter baumannii in the lung secretions culture

Exclusion Criteria

Pregnancy
Lactation
Sensitivity to meropenem, colistin, or levofloxacin
Acute Respiratory Distress Syndrome
Active pulmonary tuberculosis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Response (defined as cure or improvement or treatment failure). Timepoint: End of intervention. Method of measurement: Clinical judgment by the observation of the patient.

Secondary Outcome Measures

Name	Time	Method
Clinical Pulmonary Infection Score (CPIS). Timepoint: Before and after the intervention. Method of measurement: Questionnaire - Clinical Pulmonary Infection Scoring System.;Mortality rate during the intervention. Timepoint: The end of intervention. Method of measurement: Counting.